{"id":1021698,"date":"2026-11-17T02:33:09","date_gmt":"2026-11-17T07:33:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/"},"modified":"2026-11-17T02:33:09","modified_gmt":"2026-11-17T07:33:09","slug":"promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/","title":{"rendered":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS\u2019s Parkinson\u2019s and ALS programs<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>Cambridge, Massachusetts, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer\u2019s disease (AD), and options to apply the technology to its Parkinson\u2019s disease (PD) and amyotrophic lateral sclerosis (ALS) programs.<\/p>\n<p align=\"left\">\u201cThis partnership is in support of the long-term value of our pipeline. Our ongoing efforts with PMN310 are unaffected by this agreement and we remain committed to advancing it as an intravenous (IV) and subcutaneous product, subject to upcoming data,\u201d said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. \u201cWe believe TXP1 is among the most compelling TfR1 shuttles in development. Pairing it with antibodies that are selective for toxic misfolded proteins may provide a path to a second-generation PMN310 in AD with a more convenient subcutaneous dosing schedule and lower cost of goods and to next-generation candidates in our pipeline.\u201d<\/p>\n<p align=\"left\">TXP1 is built on a deimmunized, single-domain VNAR antibody scaffold that is significantly smaller than a conventional antibody. In preclinical studies reported by Ossianix, including studies in non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold, with no accumulation observed in the liver, spleen, lung, kidney, bone marrow, heart or muscle. Ossianix has also reported a favorable PK profile with prolonged brain exposure, binding that does not compete with transferrin, and minimal impact on reticulocyte levels, an effect that has been reported with some TfR1-targeting approaches. Based on these preclinical data, ProMIS believes TXP1 has a differentiated profile among TfR1-based shuttles.<\/p>\n<p align=\"left\">\u201cWe are proud to partner with ProMIS and see this agreement as strong validation of TXP1\u2019s profile as a next-generation TfR1-targeting delivery technology,\u201d said Frank Walsh, CEO of Ossianix. \u201cBy pairing our deimmunized VNAR platform\u2014which binds a unique epitope\u2014with ProMIS\u2019s selective antibodies, we see a compelling opportunity to enable more convenient dosing across Alzheimer\u2019s and expand into additional neurodegenerative programs.\u201d<\/p>\n<p align=\"left\">Under the terms of the agreement, Ossianix will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on global net sales. ProMIS also holds options to apply TXP1 to PMN442, its antibody targeting alpha-synuclein (implicated in Parkinson\u2019s disease and dementia with Lewy bodies), and PMN267, its antibody targeting TDP-43 (implicated in ALS and frontotemporal dementia). ProMIS intends to fund its short-term obligations under the agreement from existing cash resources and does not expect the agreement to change its previously disclosed cash runway through 2027.<\/p>\n<p align=\"left\">Destum Partners served as transaction advisor to Ossianix.<\/p>\n<p align=\"left\">\n        <strong>About ProMIS Neurosciences Inc.<\/strong>\n      <\/p>\n<p align=\"left\">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company\u2019s proprietary target discovery engine, EpiSelect\u2122, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson\u2019s disease (PD), and dementia with Lewy bodies (DLB). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).<\/p>\n<p align=\"left\">\n        <strong>About PMN310<\/strong>\n      <\/p>\n<p align=\"left\">PMN310, the Company\u2019s lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025 and is being evaluated in PRECISE-AD (NCT06750432), a randomized, double-blind, placebo-controlled Phase 1b study in patients with mild cognitive impairment due to AD or mild AD.<\/p>\n<p align=\"left\">\n        <strong>About Ossianix, Inc.<\/strong>\n      <\/p>\n<p align=\"left\">Ossianix is a privately held drug discovery and development company pioneering a new generation of brain-selective delivery technologies based on naturally occurring single-domain antibodies known as VNARs. Ossianix is headquartered in Philadelphia, Pennsylvania, with research laboratories in Stevenage, United Kingdom.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"left\">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, \u201cforward-looking information\u201d) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company\u2019s license agreement with Ossianix; the potential of the TXP1 brain-selective shuttling technology to enhance brain delivery of the Company\u2019s antibodies; the Company\u2019s belief that TXP1 has a differentiated profile among TfR1-based shuttles; the potential development of a second-generation PMN310, including the potential for a more convenient dosing schedule and lower cost of goods; the Company\u2019s plans to advance first-generation PMN310 as a subcutaneous product; the Company\u2019s ability to exercise its options and apply TXP1 to its ALS and PD programs; the achievement of milestones and payment of royalties under the agreement; the Company\u2019s expected cash runway; and the potential benefits of PMN310 and the Company\u2019s pipeline candidates. Statements containing forward-looking information are not historical facts but instead represent management\u2019s current expectations, estimates, and projections regarding the future of the business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions, and other factors that may cause actual results, level of activity, performance or achievement to differ materially from those expressed or implied, including, but not limited to, the risk that preclinical results, including results reported by Ossianix, may not be predictive of results in later studies or in humans, the risk that the licensed technology may not achieve its intended objectives, the risk that clinical data from the PRECISE-AD trial may be delayed or may not support further development or regulatory approval of PMN310, the Company\u2019s accumulated deficit, and the expectation for continued losses. Important factors that could cause actual results to differ materially are discussed in the \u201cRisk Factors\u201d section of the Company\u2019s most recently filed Annual Report on Form 10-K and in its subsequent filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p align=\"left\">\n        <strong>For Investor Relations, please contact:<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>ProMIS Neurosciences Inc.<\/strong>\n      <\/p>\n<p align=\"left\">Carie Pierce<br \/>VP, Investor Relations &amp; External Affairs<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zA2N1os_pLnqMubnTFPnOi9wdSc5ugzS-cXRMTp_4hqlwrNbrXIkqyBOKeB8uNq01B0lxoIGVk-RD1OlIqRDyQSrsjTT_gAEzlo0WyU3YTYy_sp1qGjad_up7AzdY68d\" rel=\"nofollow\" target=\"_blank\"><u>IR@promisneurosciences.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Ossianix, Inc<\/strong><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p align=\"left\">Dr. Steve Moore<br \/>COO, Ossianix, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9tBqAuqJJxGuarb4d_TirkL0l7ttKYIXt7b-NoURMAeJp6ar7_xc1U0o5jAfSefm2nop7r8jzt3XPRvPOvf0SXlbknIDCYMOb6PrX-szfxU=\" rel=\"nofollow\" target=\"_blank\"><u>steve@ossianix.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODNkNGQzYzYtZWZlYi00ZmZmLWEwZmYtM2RiMzM2OGNlY2ZiLTEwOTYxNjAtMjAyNi0xMS0xNy1lbg==\/tiny\/ProMIS-Neurosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS\u2019s Parkinson\u2019s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer\u2019s disease (AD), and options to apply the technology to its Parkinson\u2019s disease (PD) and amyotrophic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS\u2019s Parkinson\u2019s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer\u2019s disease (AD), and options to apply the technology to its Parkinson\u2019s disease (PD) and amyotrophic &hellip; Continue reading &quot;ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T07:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline\",\"datePublished\":\"2026-11-17T07:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/\"},\"wordCount\":1238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/\",\"name\":\"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\",\"datePublished\":\"2026-11-17T07:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk","og_description":"TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS\u2019s Parkinson\u2019s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer\u2019s disease (AD), and options to apply the technology to its Parkinson\u2019s disease (PD) and amyotrophic &hellip; Continue reading \"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-17T07:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline","datePublished":"2026-11-17T07:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/"},"wordCount":1238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/","name":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=","datePublished":"2026-11-17T07:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTA0NSM3OTY5OTI3IzIwODQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}